These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 36601276)

  • 1. Retracted: Effects of CIK Cell Therapy Combined with Camrelizumab on the Quality of Life in Patients with Nasopharyngeal Carcinoma and Analysis of Prognostic Factors.
    Neuroscience CIA
    Comput Intell Neurosci; 2022; 2022():9854614. PubMed ID: 36601276
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of CIK Cell Therapy Combined with Camrelizumab on the Quality of Life in Patients with Nasopharyngeal Carcinoma and Analysis of Prognostic Factors.
    Feng T; Luo X; Cao W; Man R; Feng X; Song Y
    Comput Intell Neurosci; 2022; 2022():5655009. PubMed ID: 35586106
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Retracted: Effects of Camrelizumab Combined with First-Line Chemotherapy on Serum SCC, VEGF Levels, and Adverse Reactions in Patients with Advanced Squamous Cell Carcinoma of the Lung.
    Intelligence And Neuroscience C
    Comput Intell Neurosci; 2023; 2023():9879124. PubMed ID: 37502038
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Camrelizumab (SHR-1210) alone or in combination with gemcitabine plus cisplatin for nasopharyngeal carcinoma: results from two single-arm, phase 1 trials.
    Fang W; Yang Y; Ma Y; Hong S; Lin L; He X; Xiong J; Li P; Zhao H; Huang Y; Zhang Y; Chen L; Zhou N; Zhao Y; Hou X; Yang Q; Zhang L
    Lancet Oncol; 2018 Oct; 19(10):1338-1350. PubMed ID: 30213452
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Retracted: Camrelizumab and Apatinib Combined with Radiotherapy Is Effective in Advanced Oligometastatic Non-Small-Cell Lung Cancer.
    And Alternative Medicine EC
    Evid Based Complement Alternat Med; 2023; 2023():9826952. PubMed ID: 37387848
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Camrelizumab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (CAPTAIN-1st): a multicentre, randomised, double-blind, phase 3 trial.
    Yang Y; Qu S; Li J; Hu C; Xu M; Li W; Zhou T; Shen L; Wu H; Lang J; Hu G; Luo Z; Fu Z; Qu S; Feng W; Chen X; Lin S; Zhang W; Li X; Sun Y; Lin Z; Lin Q; Lei F; Long J; Hong J; Huang X; Zeng L; Wang P; He X; Zhang B; Yang Q; Zhang X; Zou J; Fang W; Zhang L
    Lancet Oncol; 2021 Aug; 22(8):1162-1174. PubMed ID: 34174189
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Retracted: Effects of Swallowing Rehabilitation Training with a Balloon Dilation Therapy on the Deglutition Function and Quality of Life of Patients with Dysphagia after Radiotherapy for Nasopharyngeal Carcinoma.
    And Alternative Medicine EC
    Evid Based Complement Alternat Med; 2023; 2023():9834549. PubMed ID: 37501859
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Retracted: Effects of Cisplatin Combined with Metformin on Proliferation and Apoptosis of Nasopharyngeal Carcinoma Cells.
    Methods In Medicine CAM
    Comput Math Methods Med; 2023; 2023():9856726. PubMed ID: 37475936
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Retracted: Differentially Expressed Genes in Nasopharyngeal Carcinoma Tissues and Their Correlation with Recurrence and Metastasis of Nasopharyngeal Carcinoma.
    Methods In Medicine CAM
    Comput Math Methods Med; 2023; 2023():9781420. PubMed ID: 37416142
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immune checkpoint inhibition in first-line treatment for recurrent or metastatic nasopharyngeal carcinoma: A CAPTAIN-1st and JUPITER-02 trial-based cost-effectiveness analysis.
    Tian K; Han J; Wang Z; Chen J
    Oral Oncol; 2022 May; 128():105842. PubMed ID: 35428025
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Retracted: Efficacy of Cetuximab in Nasopharyngeal Carcinoma Patients Receiving Concurrent Cisplatin-Radiotherapy: A Meta-Analysis.
    Methods In Medicine CAM
    Comput Math Methods Med; 2023; 2023():9798503. PubMed ID: 37416222
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative safety and efficacy of anti-PD-1 monotherapy, chemotherapy alone, and their combination therapy in advanced nasopharyngeal carcinoma: findings from recent advances in landmark trials.
    Lv JW; Li JY; Luo LN; Wang ZX; Chen YP
    J Immunother Cancer; 2019 Jun; 7(1):159. PubMed ID: 31238988
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Retracted: Analysis of the Molecular Mechanism of
    Healthcare Engineering JO
    J Healthc Eng; 2023; 2023():9864290. PubMed ID: 37476805
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Retracted: Identification of Key Genes in Nasopharyngeal Carcinoma Based on Bioinformatics Analysis.
    Intelligence And Neuroscience C
    Comput Intell Neurosci; 2023; 2023():9836790. PubMed ID: 38074350
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Retracted: Effects of Self-Care plus Forecasting Nursing on the Treatment Outcomes and Emotions in Patients with Nasopharyngeal Carcinoma after Radiotherapy.
    And Alternative Medicine EC
    Evid Based Complement Alternat Med; 2023; 2023():9847364. PubMed ID: 38093884
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Retracted] MicroRNA‑425 is downregulated in nasopharyngeal carcinoma and regulates tumor cell viability and invasion by targeting hepatoma‑derived growth factor.
    Zhu W; Ma Y; Zhuang X; Jin X
    Oncol Lett; 2024 Mar; 27(3):112. PubMed ID: 38304176
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Retracted: Effect of Body Size Change on Off-Center Cervical Point and Face Doses in Patients Undergoing Nasopharyngeal Carcinoma Radiotherapy.
    Markers D
    Dis Markers; 2023; 2023():9836583. PubMed ID: 37502571
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Retracted: Timosaponin AIII Suppresses RAP1 Signaling Pathway to Enhance the Inhibitory Effect of Paclitaxel on Nasopharyngeal Carcinoma.
    Methods In Medicine CAM
    Comput Math Methods Med; 2023; 2023():9804984. PubMed ID: 37416199
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Retracted: Prediction of Changes in Tumor Regression during Radiotherapy for Nasopharyngeal Carcinoma by Using the Computed Tomography-Based Radiomics.
    Imaging CMM
    Contrast Media Mol Imaging; 2023; 2023():9809608. PubMed ID: 37547642
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Retracted: Integrated Analysis of the Roles of RNA Binding Proteins and Their Prognostic Value in Clear Cell Renal Cell Carcinoma.
    Healthcare Engineering JO
    J Healthc Eng; 2023; 2023():9828737. PubMed ID: 37266270
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.